KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Intangibles (2017 - 2025)

BeOne Medicines (ONC) has disclosed Change in Intangibles for 5 consecutive years, with $20.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Change in Intangibles changed N/A to $20.0 million in Q2 2025 year-over-year; TTM through Dec 2025 was $20.0 million, a 327.9% increase, with the full-year FY2025 number at $20.0 million, up 327.9% from a year prior.
  • Change in Intangibles was $20.0 million for Q2 2025 at BeOne Medicines, up from $4.7 million in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of $20.0 million in Q2 2025 to a low of $4.7 million in Q1 2024.
  • A 3-year average of $11.0 million and a median of $9.7 million in 2023 define the central range for Change in Intangibles.